JP2024506382A5 - - Google Patents
Info
- Publication number
- JP2024506382A5 JP2024506382A5 JP2023548868A JP2023548868A JP2024506382A5 JP 2024506382 A5 JP2024506382 A5 JP 2024506382A5 JP 2023548868 A JP2023548868 A JP 2023548868A JP 2023548868 A JP2023548868 A JP 2023548868A JP 2024506382 A5 JP2024506382 A5 JP 2024506382A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- less
- decanoate
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163149550P | 2021-02-15 | 2021-02-15 | |
| US63/149,550 | 2021-02-15 | ||
| PCT/US2022/016278 WO2022174134A1 (en) | 2021-02-15 | 2022-02-14 | Abiraterone prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506382A JP2024506382A (ja) | 2024-02-13 |
| JP2024506382A5 true JP2024506382A5 (https=) | 2025-02-19 |
Family
ID=80625499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548868A Pending JP2024506382A (ja) | 2021-02-15 | 2022-02-14 | アビラテロンプロドラッグ |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11957696B2 (https=) |
| EP (1) | EP4291159A1 (https=) |
| JP (1) | JP2024506382A (https=) |
| CN (1) | CN117120034A (https=) |
| CA (1) | CA3207282A1 (https=) |
| WO (1) | WO2022174134A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| US10792292B2 (en) | 2019-03-06 | 2020-10-06 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN116490165A (zh) * | 2020-09-02 | 2023-07-25 | 普洛佩拉治疗公司 | 阿比特龙前药 |
| US11957696B2 (en) | 2021-02-15 | 2024-04-16 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| JP2024533332A (ja) * | 2021-09-08 | 2024-09-12 | プロペラ セラピューティクス インコーポレイテッド | 経口アビラテロン製剤 |
| CA3243913A1 (en) | 2022-03-01 | 2023-09-07 | Astellas Us Llc | Abiraterone prodrugs |
| JP2026500894A (ja) * | 2022-10-24 | 2026-01-09 | アルヴィナス・オペレーションズ・インコーポレイテッド | アンドロゲン受容体の標的分解のための化合物及び方法 |
| WO2024107928A1 (en) | 2022-11-16 | 2024-05-23 | Propella Therapeutics, Inc. | Abiraterone decanoate composition and use in therapy |
| CN116046950A (zh) * | 2023-01-18 | 2023-05-02 | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 一种检测醋酸阿比特龙中5种杂质的方法 |
| WO2024186523A2 (en) * | 2023-03-07 | 2024-09-12 | Board Of Regents, The University Of Texas System | Glucocorticoid receptor antagonists for cancer treatment |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4432987A (en) * | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| PT1955700E (pt) * | 1999-09-30 | 2011-05-04 | Harbor Biosciences Inc | Tratamento terap?utico de doen?as associadas ao receptor de androg?nios |
| JP2004002321A (ja) * | 2002-03-11 | 2004-01-08 | Takeda Chem Ind Ltd | 性ホルモン依存性疾患治療剤 |
| GB0418900D0 (en) | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| US20090124587A1 (en) | 2007-07-12 | 2009-05-14 | Auerbach Alan H | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS |
| CN102686600A (zh) | 2009-02-05 | 2012-09-19 | 托凯药业股份有限公司 | 甾体cyp17抑制剂/抗雄激素物质的新型药物前体 |
| CA2782266A1 (en) | 2009-11-30 | 2011-06-03 | Harbor Biosciences, Inc. | Anticancer compounds and screening method |
| EP2651916A2 (en) | 2010-12-16 | 2013-10-23 | BioMarin Pharmaceutical Inc. | C-17-heteroaryl steroidal compounds as inhibitors of cyp11b, cyp17, and/or cyp21 |
| CN104066744B (zh) | 2011-10-10 | 2017-03-22 | 扎克系统公司 | 用于制备17‑取代的甾体的方法 |
| US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| EP2841444A4 (en) | 2012-04-23 | 2015-11-04 | Alphora Res Inc | PROCESS FOR PREPARING 17-SUBSTITUTED STEROIDS |
| WO2014009434A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
| US20140011992A1 (en) | 2012-12-20 | 2014-01-09 | Crystal Pharma, S.A.U. | Synthesis of abiraterone and related compounds |
| PL2945628T3 (pl) * | 2013-01-15 | 2020-09-21 | Aragon Pharmaceuticals, Inc. | Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza |
| WO2014111815A2 (en) | 2013-01-18 | 2014-07-24 | Cortendo Ab (Publ) | Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction |
| US20140287039A1 (en) | 2013-03-15 | 2014-09-25 | Iceutica Inc. | Abiraterone Acetate Formulation |
| US20150246060A1 (en) | 2013-03-15 | 2015-09-03 | Iceutica Inc. | Abiraterone Acetate Formulation and Methods of Use |
| EP3738594A1 (en) | 2013-09-10 | 2020-11-18 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics having an hsp90 ligand as binding moiety |
| US20150157646A1 (en) | 2013-09-27 | 2015-06-11 | Iceutica Inc. | Abiraterone Steroid Formulation |
| JP6576942B6 (ja) | 2014-03-03 | 2019-11-27 | マドリガル ファーマシューティカルズ インコーポレイテッド | 標的治療薬 |
| MA39483A (fr) | 2014-03-18 | 2015-09-24 | Synta Pharmaceuticals Corp | Agents thérapeutiques cibles |
| CN104017045B (zh) | 2014-06-23 | 2016-01-13 | 广州艾格生物科技有限公司 | 甾体cyp17抑制剂的新型药物前体及其应用、制备方法 |
| US9937259B2 (en) | 2014-06-27 | 2018-04-10 | Zhuhai Beihai Biotech Co., Ltd. | Abiraterone derivatives and non-covalent complexes with albumin |
| SG11201701139YA (en) | 2014-09-18 | 2017-03-30 | Iceutica Inc | Abiraterone acetate formulation and methods of use |
| CN104356191A (zh) | 2014-09-29 | 2015-02-18 | 上海延安药业（湖北）有限公司 | 阿比特龙单琥珀酸酯及其制备方法 |
| CN106061990B (zh) | 2014-11-28 | 2019-09-10 | 四川海思科制药有限公司 | 一种阿比特龙衍生物及其制备方法和医药用途 |
| CN104710499A (zh) | 2015-02-15 | 2015-06-17 | 重庆医药工业研究院有限责任公司 | 一种丙酸阿比特龙的晶型及其制备方法 |
| EP3394080B1 (en) | 2015-12-23 | 2023-06-07 | The University Of British Columbia | Lipid-linked prodrugs |
| CN108541255B (zh) | 2016-02-02 | 2019-06-14 | 深圳市塔吉瑞生物医药有限公司 | 一种甾体类化合物及包含该化合物的组合物及其用途 |
| US10717762B2 (en) | 2016-10-11 | 2020-07-21 | Zhuhai Beihai Biotech Co., Ltd. | Abiraterone derivative and formulations thereof |
| CN106977577A (zh) | 2017-04-21 | 2017-07-25 | 湖南师范大学 | 两类阿比特龙衍生物的合成 |
| JOP20200072A1 (ar) * | 2017-10-11 | 2020-04-29 | Janssen Oncology Inc | طرق علاج سرطان البروستاتا من خلال إعطاء أسيتات الأبيراتيرون إلى جانب البريدنيزون مع المعالجة بحرمان الأندروجين |
| WO2020081999A1 (en) | 2018-10-18 | 2020-04-23 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| EP3914234A4 (en) | 2019-01-25 | 2022-09-14 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical compositions |
| US10792292B2 (en) * | 2019-03-06 | 2020-10-06 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| AU2020240017A1 (en) * | 2019-03-18 | 2021-11-04 | AustinPx, LLC | Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof |
| CN116490165A (zh) * | 2020-09-02 | 2023-07-25 | 普洛佩拉治疗公司 | 阿比特龙前药 |
| CN113929727A (zh) | 2020-09-28 | 2022-01-14 | 南京易腾药物研究院有限公司 | 阿比特龙酯类衍生物及其制备方法和应用 |
| US11957696B2 (en) * | 2021-02-15 | 2024-04-16 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| JP2024533332A (ja) | 2021-09-08 | 2024-09-12 | プロペラ セラピューティクス インコーポレイテッド | 経口アビラテロン製剤 |
-
2022
- 2022-02-14 US US17/670,712 patent/US11957696B2/en active Active
- 2022-02-14 WO PCT/US2022/016278 patent/WO2022174134A1/en not_active Ceased
- 2022-02-14 EP EP22707562.9A patent/EP4291159A1/en active Pending
- 2022-02-14 CA CA3207282A patent/CA3207282A1/en active Pending
- 2022-02-14 CN CN202280028179.4A patent/CN117120034A/zh active Pending
- 2022-02-14 JP JP2023548868A patent/JP2024506382A/ja active Pending
-
2023
- 2023-07-26 US US18/226,339 patent/US20240139212A1/en active Pending
-
2025
- 2025-09-17 US US19/331,393 patent/US20260014172A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024506382A5 (https=) | ||
| JP4680891B2 (ja) | 許容可能な血清中テストステロン・レベルを信頼性高く達成するための方法及び医薬組成物 | |
| EP3265127B1 (en) | Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor | |
| EP1313511B1 (en) | Testosterone ester formulation for human use | |
| CN1394141A (zh) | Fulvestrant制剂 | |
| BR112012025961B1 (pt) | Composição farmacêutica oral | |
| JP2023539371A5 (https=) | ||
| JP2024533332A5 (https=) | ||
| EP4486353A1 (en) | Abiraterone decanoate prodrugs and use in therapy | |
| RU2024129008A (ru) | Пролекарства абиратерона деканоата и их применение в терапии | |
| HK40120426A (zh) | 阿比特龙前药 | |
| HK1099230A (en) | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels | |
| Sternberg | New targets and drugs in prostate cancer | |
| HK1069325B (en) | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels | |
| HK1248128B (en) | Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor |